Embecta (EMBC) to Release Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $256.08 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Embecta (NASDAQ:EMBC) last issued its earnings results on Tuesday, November 26th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.05. The business had revenue of $286.10 million for the quarter, compared to analysts’ expectations of $276.97 million. Embecta had a negative return on equity of 18.54% and a net margin of 6.97%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.59 EPS. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Price Performance

Shares of Embecta stock opened at $18.27 on Wednesday. The stock has a market cap of $1.06 billion, a P/E ratio of 13.53, a P/E/G ratio of 0.97 and a beta of 1.20. The stock’s 50 day simple moving average is $19.75 and its 200-day simple moving average is $16.51. Embecta has a 1-year low of $9.93 and a 1-year high of $21.48.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th were issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 3.28%. The ex-dividend date was Friday, December 6th. Embecta’s dividend payout ratio is currently 44.44%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Morgan Stanley upgraded Embecta from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $13.00 to $20.00 in a report on Monday, December 2nd. BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Wednesday, November 27th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.